INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596276
Filing Date		2006-06-08
First Named Inventor	BRO	CKEL, Michael D.
Art Unit		
Examiner Name	Unas	signed
Attorney Docket Numb	er	306436

	U.S.PATENTS Remove							
		Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	D233469		1974-10-29	Moore, Arthur H.			
	2	D293027		1987-12-01	Zurwelle, Donald W.			
	3	D363360		1995-10-17	Santarsiero, Paul S.			
	4	D368540		1996-04-02	Santarsiero, Paul S.			
	5	D370988		1996-06-18	Santarsiero, Paul S.			
	6	D371448		1996-07-02	Santarsiero, Paul S.			
	7	D373210		1996-08-27	Santarsiero, Paul S.			
	8	D379542		1997-05-27	Egashira, Teruaki			

#### First Named Inventor BROCKEL Michael D. STATEMENT BY APPLICANT Art I Init ( Not for submission under 37 CFR 1.99) Examiner Name Unassigned Attorney Docket Number 306436 D403442 1998-12-29 Joss Michael S 10 D450871 2001-11-20 Dairet al 2002-06-04 11 D458408 China Yueh Add If you wish to add additional U.S. Patent citation information please click the Add button. Remove HIS PATENT APPLICATION PHRI ICATIONS Pages, Columns, Lines where Kind Publication Name of Patentee or Applicant Examiner Cite Publication Number Relevant Passages or Relevant Initial\* No Code<sup>1</sup> Date of cited Document Figures Appear If you wish to add additional U.S. Published Application citation information please click the Add button. Add FOREIGN PATENT DOCUMENTS Pages, Columns, Lines Name of Patentee or Kind Publication where Relevant Examiner Cite Foreign Document Country Applicant of cited No Initial\* Number<sup>3</sup> Code<sup>2</sup> i Code4 Date Passages or Relevant Document Figures Appear If you wish to add additional Foreign Patent Document citation information please click the Add button Add NON-PATENT LITERATURE DOCUMENTS Remove Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), T5 Initials\* No publisher, city and/or country where published.

Application Number

Filing Date

INFORMATION DISCLOSURE

10596276

2006-06-08

	Application Number		10596276
INFORMATION DIGGS COURT	Filing Date		2006-06-08
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	BRO	CKEL, Michael D.
(Not for submission under 37 CFR 1.99)	Art Unit		
(Not lot submission direct or or it issue	Examiner Name Unas		signed
	Attorney Docket Numb	er	306436

EXAMINER SIGNATURE					
Examiner Signature			Date Considered		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a					

If you wish to add additional non-patent literature document citation information please click the Add button Add

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Patent Documents at Invest USPTO, GOLV or MPEP 901.04. 2 Enter office that issued the document, by the Involved (WIPO Standard ST3.). 3 "For Judgmense plant for Judgmens plant for

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596276
Filing Date		2006-06-08
First Named Inventor	BRO	CKEL, Michael D.
Art Unit		
Examiner Name	Unas	signed
Attorney Docket Number		306436

#### CERTIFICATION STATEMENT

Please see 37	CFR 1	1.97 and	1.98 to	make the ag	ppropriate	selection(	s)
---------------	-------	----------	---------	-------------	------------	------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

### ΩR

That no item of Information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person spinifip the certification after making reasonable inquiry, no tern of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1,579(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Roger D. Wylie/	Date (YYYY-MM-DD)	2006-10-06
Name/Print	Roger D. Wylie	Registration Number	36974

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sciences, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via filed in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.